AstraZeneca Anticoagulant NDA Delayed; Crestor v. Lipitor Data In March
AstraZeneca plans to submit an NDA for the oral direct thrombin inhibitor H376/95 in the second half of 2002.
AstraZeneca plans to submit an NDA for the oral direct thrombin inhibitor H376/95 in the second half of 2002.